# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): November 20, 2003

# AMERICAN VANGUARD CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 0-6354 95-2588080

(State or other jurisdiction of incorporation) Commission File Number (I.R.S. Employer Identification No.)

**4695 MacArthur Court** 

Newport Beach, California 92660

# Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

 $(Address\ of\ principal\ executive\ of fices)$ 

Registrant s telephone number: (949) 260-1200

# Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

#### Item 5. Other Events.

On November 20, 2003, American Vanguard Corporation issued the press release attached hereto as Exhibit 99.4. The release announced that Amvac Chemical Corporation, a wholly-owned subsidiary of American Vanguard Corporation, has signed a definitive agreement to acquire certain assets related to the active ingredient dichlorvos ( DDVP ) used in the animal health business and marketed primarily under the trade name Nuvan® from Novaritas Animal Health, Inc., all as more particularly described in Exhibit 99.4.

#### Item 7. Exhibits.

99.4 Press release issued November 20, 2003.

2

# Edgar Filing: AMERICAN VANGUARD CORP - Form 8-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMERICAN VANGUARD CORPORATION

(Registrant)

By: /s/ JAMES A. BARRY

James A. Barry

Senior Vice President

**Chief Financial Officer** 

Date: November 24, 2003

## INDEX TO EXHIBITS

### Exhibit

No.	Description
99.4	Press release

4